Journal Article Review Epublish 42 citations
PubMed: 33317050 DOI: 10.3390/ijms21249375
Adiponectin in Chronic Kidney Disease.
Int J Mol Sci 21(24)
Authors: Jarosław Przybyciński, Violetta Dziedziejko, Kamila Puchałowicz, Leszek Domański, Andrzej Pawlik
Affiliations
- Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University in Szczecin, Powstańców Wlkp. 72, 70-111 Szczecin, Poland.
- Department of Biochemistry and Medical Chemistry, Pomeranian Medical University in Szczecin, Powstańców Wlkp. 72, 70-111 Szczecin, Poland.
- Department of Physiology, Pomeranian Medical University in Szczecin, Powstańców Wlkp. 72, 70-111 Szczecin, Poland.
Abstract
Adiponectin is the adipokine associated with insulin sensitization, reducing liver gluconeogenesis, and increasing fatty acid oxidation and glucose uptake. Adiponectin is present in the kidneys, mainly in the arterial endothelium and smooth muscle cells, as well as in the capillary endothelium, and might be considered as a marker of many negative factors in chronic kidney disease. The last few years have brought a rising body of evidence that adiponectin is a multipotential protein with anti-inflammatory, metabolic, anti-atherogenic, and reactive oxygen species (ROS) protective actions. Similarly, adiponectin has shown many positive and direct actions in kidney diseases, and among many kidney cells. Data from large cross-sectional and cohort studies showed a positive correlation between serum adiponectin and mortality in chronic kidney disease. This suggests a complex interaction between local adiponectin action, comorbidities, and uremic milieu. In this review we discuss the role of adiponectin in chronic kidney disease.
MeSH
Transplantation, Endothelium, Kidney Diseases, Cells, Atherosclerosis, Obesity, Receptors, Adiponectin
Cited by
- Serum concentrations of leptin and adiponectin in dogs with chronic kidney disease. J Vet Intern Med, 2022
- Targeting Adiponectin in Breast Cancer. Biomedicines, 2022
- Obesity-Related Kidney Disease: A Growing Threat to Renal Health. Int J Mol Sci, 2025
- Comprehensive strategy for identifying extracellular vesicle surface proteins as biomarkers for chronic kidney disease. Front Physiol, 2024
- Association of Serum Adipokines and Resting Energy Expenditure in Patients With Chronic Kidney Disease. Front Nutr, 2022
- Adiponectin inhibits the activation of lung fibroblasts and pulmonary fibrosis by regulating the nuclear factor kappa B (NF-κB) pathway. Bioengineered, 2022
- Adiponectin: a pleiotropic hormone with multifaceted roles. Probl Endokrinol (Mosk), 2022
- Sex differences in obesity-induced renal lipid accumulation revealed by lipidomics: a role of adiponectin/AMPK axis. Biol Sex Differ, 2023
- Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1-Adiponectin Axis. Front Endocrinol (Lausanne), 2022
- Association of serum adiponectin and leptin levels with renal function in kidney transplant recipients with or without new-onset diabetes after transplantation. J Clin Lab Anal, 2021
- The Effect of Kidney Transplantation and Immunosuppressive Therapy on Adipose Tissue Content and Adipocytokine Plasma Concentration-Preliminary Study. Curr Issues Mol Biol, 2025
- Reevaluating Adiponectin's impact on obesity hypertension: a Chinese case-control study. BMC Cardiovasc Disord, 2024
- A Mixture of Pure, Isolated Polyphenols Worsens the Insulin Resistance and Induces Kidney and Liver Fibrosis Markers in Diet-Induced Obese Mice. Antioxidants (Basel), 2022
- Impact of Obesity in Kidney Diseases. Nutrients, 2022
- Improved Glycaemic Control and Nephroprotective Effects of Empagliflozin and Paricalcitol Co-Therapy in Mice with Type 2 Diabetes Mellitus. Int J Mol Sci, 2023